

Special Issue

New Advances in Neuropharmacology

Message from the Guest Editors

This Special Issue aims to showcase cutting-edge research in neuropharmacology, focusing on novel therapeutic strategies, molecular mechanisms, and translational innovations for neurological and psychiatric disorders. With rapid advancements in understanding neural circuitry, neuroinflammation, and synaptic plasticity, this field holds immense potential to address unmet clinical needs in conditions such as Parkinson's disease and Alzheimer's disease, psychological disorders, and many others.

We invite original research articles, reviews, and perspectives that explore emerging drug targets, innovative drug delivery systems, biomarker discovery, and the application of AI/ML in drug design.

Contributions addressing pharmacogenomics, neuroprotection, and the repurposing of existing therapeutics are particularly encouraged. Submissions should emphasize mechanistic insights, preclinical-to-clinical translation, and implications for precision medicine.

Authors are welcome to submit manuscripts aligned with these themes. All submissions will undergo rigorous peer review to ensure scientific rigor and relevance. Join us in advancing the field of neuropharmacology!

Guest Editors

Dr. Yu-Cheng Ho

School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan

Dr. Ming Tatt Lee

Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia

Deadline for manuscript submissions

closed (30 April 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/236258

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).